ArticleMolecular oncology2013

Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.

Erik Laurini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.